|
1
|
Powell WC, Hicks DG, Prescott N, Tarr SM,
Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, et
al: A new rabbit monoclonal antibody (4B5) for the
immunohistochemical (IHC) determination of the HER2 status in
breast cancer: Comparison with CB11, fluorescence in situ
hybridization (FISH), and interlaboratory reproducibility. Appl
Immunohistochem Mol Morphol. 15:94–102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pauletti G, Godolphin W, Press MF and
Slamon DJ: Detection and quantitation of HER-2/neu gene
amplification in human breast cancer archival material using
fluorescence in situ hybridization. Oncogene. 13:63–72.
1996.PubMed/NCBI
|
|
4
|
Yarden Y: Biology of HER2 and its
importance in breast cancer. Oncology. 61(Suppl 2): S1–S13. 2001.
View Article : Google Scholar
|
|
5
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eccles SA: The role of c-erbB-2/HER2/neu
in breast cancer progression and metastasis. J Mammary Gland Biol
Neoplasia. 6:393–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dendukuri N, Khetani K, McIsaac M and
Brophy J: Testing for HER2-positive breast cancer: A systematic
review and cost-effectiveness analysis. CMAJ. 176:1429–1434. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ross JS and Fletcher JA: The HER-2/neu
oncogene in breast cancer: Prognostic factor, predictive factor,
and target for therapy. Stem Cells. 16:413–428. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cobleigh MA, Vogel CL, Tripathy D, Robert
NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman
G and Slamon DJ: Multinational study of the efficacy and safety of
humanized anti-HER2 monoclonal antibody in women who have
HER2-overexpressing metastatic breast cancer that has progressed
after chemotherapy for metastatic disease. J Clin Oncol.
17:2639–2648. 1999.PubMed/NCBI
|
|
10
|
Pauletti G, Dandekar S, Rong H, Ramos L,
Peng H, Seshadri R and Slamon DJ: Assessment of methods for
tissue-based detection of the HER-2/neu alteration in human breast
cancer: A direct comparison of fluorescence in situ hybridization
and immunohistochemistry. J Clin Oncol. 18:3651–3664.
2000.PubMed/NCBI
|
|
11
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldhirsch A, Gelber RD, Piccart-Gebhart
MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D,
Weber HA, Heinzmann D, et al: 2 years versus 1 year of adjuvant
trastuzumab for HER2-positive breast cancer (HERA): An open-label,
randomised controlled trial. Lancet. 382:1021–1028. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bloom KJ and Cote RJ: Counterpoint: Both
immunohistochemistry and fluorescence in situ hybridization play
important roles for HER2 evaluation. Clin Chem. 57:983–985. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garrison LP Jr, Lalla D, Brammer M,
Babigumira JB, Wang B and Perez EA: Assessing the potential
cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early
stage breast cancer patients for HER2 status. Cancer.
119:3113–3122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brunello E, Bogina G, Bria E, Vergine M,
Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi
M, et al: The identification of a small but significant subset of
patients still targetable with anti-HER2 inhibitors when affected
by triple negative breast carcinoma. J Cancer Res Clin Oncol.
139:1563–1568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iorfida M, Dellapasqua S, Bagnardi V,
Cardillo A, Rotmensz N, Mastropasqua MG, Bottiglieri L, Goldhirsch
A, Viale G and Colleoni M: HER2-negative (1+) breast cancer with
unfavorable prognostic features: To FISH or not to FISH? Ann Oncol.
23:1371–1372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartlett JM, Ibrahim M, Jasani B, Morgan
JM, Ellis I, Kay E, Connolly Y, Campbell F, O'Grady A, Barnett S
and Miller K: External quality assurance of HER2 FISH and ISH
testing: Three years of the UK national external quality assurance
scheme. Am J Clin Pathol. 131:106–111. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tinoco G, Warsch S, Glück S, Avancha K and
Montero AJ: Treating breast cancer in the 21st century: Emerging
biological therapies. J Cancer. 4:117–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: Panel members: Thresholds for
therapies: Highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jalava P, Kuopio T, Juntti-Patinen L,
Kotkansalo T, Kronqvist P and Collan Y: Ki67 immunohistochemistry:
A valuable marker in prognostication but with a risk of
misclassification: Proliferation subgroups formed based on Ki67
immunoreactivity and standardized mitotic index. Histopathology.
48:674–682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rakha EA, Starczynski J, Lee AH and Ellis
IO: The updated ASCO/CAP guideline recommendations for HER2 testing
in the management of invasive breast cancer: A critical review of
their implications for routine practice. Histopathology.
64:609–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lambein K, Van Bockstal M, Denys H and
Libbrecht L: 2013 update of the American Society of Clinical
Oncology/College of American Pathologists guideline for human
epidermal growth factor receptor 2 testing: Impact on
immunohistochemistry-negative breast cancers. J Clin Oncol.
32:1856–1857. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perez EA, Cortés J, Gonzalez-Angulo AM and
Bartlett JM: HER2 testing: Current status and future directions.
Cancer Treat Rev. 40:276–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu JM, Halushka MK and Argani P:
Intratumoral heterogeneity of HER-2 gene amplification and protein
overexpression in breast cancer. Hum Pathol. 41:914–917. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vance GH, Barry TS, Bloom KJ, Fitzgibbons
PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR and Hammond ME:
College of American Pathologists: Genetic heterogeneity in HER2
testing in breast cancer: Panel summary and guidelines. Arch Pathol
Lab Med. 133:611–612. 2009.PubMed/NCBI
|
|
32
|
Bartlett AI, Starcyznski J, Robson T,
Maclellan A, Campbell FM, van de Velde CJ, Hasenburg A, Markopoulos
C, Seynaeve C, Rea D and Bartlett JM: Heterogeneous HER2 gene
amplification: Impact on patient outcome and a clinically relevant
definition. Am J Clin Pathol. 136:266–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee S, Jung W, Hong SW and Koo JS:
Evaluation of intratumoral HER-2 heterogeneity by fluorescence in
situ hybridization in invasive breast cancer: A single institution
study. J Korean Med Sci. 26:1001–1006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ohlschlegel C, Zahel K, Kradolfer D, Hell
M and Jochum W: HER2 genetic heterogeneity in breast carcinoma. J
Clin Pathol. 64:1112–1126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Starczynski J, Atkey N, Connelly Y,
O'Grady T, Campbell FM, di Palma S, Wencyk P, Jasani B, Gandy M and
Bartlett JM: UKNEQAS: HER2 gene amplification in breast cancer: A
rogues' gallery of challenging diagnostic cases: UKNEQAS
interpretation guidelines and research recommendations. Am J Clin
Pathol. 137:595–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bussolati G, Annaratone L and Maletta F:
The pre-analytical phase in surgical pathology. Recent Results
Cancer Res. 199:1–13. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: Recommendations from the
International Ki67 in breast cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tashima R, Nishimura R, Osako T, Nishiyama
Y, Okumura Y, Nakano M, Fujisue M, Toyozumi Y and Arima N:
Evaluation of an optimal cut-off point for the Ki-67 index as a
prognostic factor in primary breast cancer: A retrospective study.
PLoS One. 10:e01195652015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members:
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
